IMMX
Immix Biopharma, Inc.
Biotechnology · Healthcare · United States
7.68
close · 2026-10-30
value
94
cheaper than peers94
quality
58
stronger fundamentals58
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 3 years ago | -1.2% | 92 |
| cash flow yield, 2 years ago | -1.8% | 92 |
| cash flow yield, 1 year ago | -2.5% | 87 |
| cash flow yield, latest year | -3.9% | 86 |
| earnings yield, 3 years ago | -7.7% | 79 |
| earnings yield, 1 year ago | -9.9% | 72 |
| earnings yield, 2 years ago | -11.6% | 71 |
| earnings yield, latest year | -11.6% | 66 |
| price to book | 2.40× | 51 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 1.2% | 70 |
| operating margin | 0.0% | 50 |
| return on equity | -74.5% | 44 |
3 of 4 measures available
Facts
| market cap | $637M |
| free cash flow | -$20.3M |
| employees | 21 |
| first trade | 2021-12-16 |
| next earnings | not reported |
| fundamentals updated | 2026-07-29 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -0.89 | -0.76 | -0.89 | -0.59 | not reported |
| free cash flow | -$24.7M | -$15.8M | -$11.4M | -$7.4M | not reported |
| net income | -$29.4M | -$21.6M | -$15.4M | -$8.2M | not reported |
| revenue | $0 | $0 | $0 | $0 | not reported |
| unusual items | not reported | not reported | not reported | $0 | -$22.8M |